
TARGET Randomized On-Site CT FFR Trial Results
New data from the TARGET trial, the first randomized trial to assess on-site machine learning-based CT-FFR strategy in CAD management.
New data from the TARGET trial, the first randomized trial to assess on-site machine learning-based CT-FFR strategy in CAD management.
Deep-learning-based, non-invasive, accurate, and accessible FFR CT analysis DEEPVESSEL FFR is now available in the USA.
Keya Medical US celebrates the achievements of the team in China and their commitment to the commercialization of DEEPVESSEL FFR.
Seattle, WA– April 1, 2022– Keya Medical announced that DEEPVESSEL FFR (DVFFR), has been cleared by U.S. Food and Drug Administration (FDA).
Keya Medical’s computer scientists, working with colleagues at the Shenzhen Second People’s Hospital, have devised a new method that significantly boosts segmentation accuracy and performance.
Recent Comments